Mostly Markets
Subscribe
Stocks/Health Care/Pharmaceuticals

Bristol Myers SquibbBMY

Pharmaceuticals · New York City, New York · In the S&P 500
Solid businessCheaper than peers
$62.48+1.78%After hours: $62.55 (+0.11%)At the close, 30 Oct · Prices from CNBC, may be delayed
▲ 46.7% over 1 year
Bristol Myers Squibb over 1 yearDaily close, $, to 30 Oct 2026
$50$60Nov2026MarMayJulSep$62.48$50$60NovMarJul$62.48
Source: Nasdaq daily closes
Market value$128B
Price to earnings13.8x
Forward P/E10.5x
Dividend yield4.03%
Year to date+15.8%
One year+46.7%
Next earningsNot scheduled
SectorHealth Care
52-week range (closes)
$45.59$68.09

Quality and valuation

How Bristol Myers Squibb compares with other health care stocks. A description, not a recommendation.

Bristol Myers Squibb and 4 pharmaceuticals peers. Across: valuation (P/E) against the sector. Up: business quality against the sector. Hover or tap a logo for its numbers.

Business quality: about averageValuation: cheaper than most

An average business among health care companies, priced below most of them.

Bristol Myers Squibb trades at 10.5 times the next 12 months of expected earnings, against a median of 19.1x for the 65 health care stocks we cover. The quality score blends where it ranks on revenue growth, gross margin, operating margin and free-cash-flow margin (net margin for banks and insurers) over the last 12 months, from SEC filings.

  • Revenue grew slower than the sector median: +4.2% vs +7.8%
  • Keeps more of each sale (gross margin): 69.2% vs 65.3%
  • Turns more of its sales into cash: 18.6% vs 15.9%
  • Keeps more of its revenue as profit (net margin): 18.5% vs 9.7%
BMY trades at 10.5x forward earnings, below the sector medianForward p/e, Pharmaceuticals peers
BMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1xBMY10.5xPFE11.1xNVO12.2xNVS17.0xAZN17.5xMRK18.1xJNJ25.1xLLY36.3xSector median 19.1x
Source: CNBC quotes; Mostly Markets

Financials

From Bristol Myers Squibb's SEC filings, through the quarter ending 30 Sep 2026. Hover or tap a bar for its value.

Revenue grew 6.9% from a year earlierQuarterly revenue, $bn, latest Q3 ’26
$0bn$5bn$10bnQ4 ’24Q2 ’25Q4 ’25$13.1bnQ3 ’26$0bn$5bn$10bnQ4 ’24Q2 ’25Q4 ’25$13.1bnQ3 ’26
Source: SEC filings
Growth sped up to +6.9% last quarterRevenue growth, year on year, %
−5%0%5%Q4 ’24Q2 ’25Q4 ’256.9%Q3 ’26−5%0%5%Q4 ’24Q2 ’25Q4 ’256.9%Q3 ’26
Source: SEC filings
Free cash flow was $9.3 billion over 12 monthsQuarterly free cash flow (operating cash flow minus capex), $bn
$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$3.8bnQ3 ’26$0bn$2bn$4bnQ4 ’24Q2 ’25Q4 ’25$3.8bnQ3 ’26
Source: SEC filings
Diluted EPS was $1.05 last quarterQuarterly diluted earnings per share, $
$0.0$0.5$1.0$1.5Q4 ’24Q2 ’25Q4 ’25$1.05Q3 ’26$0$1Q4 ’24Q2 ’25Q4 ’25$1.05Q3 ’26
Source: SEC filings
Last 12 monthsBMYSector median
Revenue growth+4.2%+7.8%
Gross margin69.2%65.3%
Free cash flow margin18.6%15.9%
Price to earnings13.8x30.2x

Stories on Bristol Myers Squibb

Friday, 30 October
Earnings

Bristol Myers Squibb (BMY) Tops Q3 Estimates as Eliquis Sales Grow 26%

Bristol Myers Squibb's revenue rose 7% to $13.07 billion, beating the $12.56 billion Zacks consensus, and it raised its 2026 sales forecast. The stock rose 1.4% on Thursday.

BMY▲ 1.4%
A capsule pill opening like a flower as small pills float up

Similar companies

Pharmaceuticals, by market value.

CompanyPriceTodayYTDValue
LLYEli Lilly$1,417.54+3.19%+31.9%$1.33T
JNJJohnson & Johnson$273.20−0.73%+32.0%$658B
MRKMerck$149.52+2.18%+42.0%$369B
NVSNovartis$160.79−0.19%+16.6%$327B
AZNAstraZeneca$186.65+7.02%+6.4%$290B
PFEPfizer$30.52+1.90%+22.6%$174B
NVONovo Nordisk$40.00+2.20%−21.4%$136B
ZTSZoetis$79.72+1.85%−36.6%$32.94B